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This study estimated the costs and incremental cost per case detected of screening strate-
gies for high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV
(WLHIV) attending HIV clinics in Burkina Faso.
Methods
The direct healthcare provider costs of screening tests (visual inspection with acetic acid
(VIA), VIA combined visual inspection with Lugol’s iodine (VIA/VILI), cytology and a rapid
HPV DNA test (careHPV)) and confirmatory tests (colposcopy, directed biopsy and system-
atic four-quadrant (4Q) biopsy) were collected alongside the HPV in Africa Research Part-
nership (HARP) study. A model was developed for a hypothetical cohort of 1000 WLHIV
using data on CIN2+ prevalence and the sensitivity of the screening tests. Costs are
reported in USD (2019).
Results
The study enrolled 554 WLHIV with median age 36 years (inter-quartile range, 31–41) and
CIN2+ prevalence of 5.8%. The average cost per screening test ranged from US$3.2 for
VIA to US$24.8 for cytology. Compared to VIA alone, the incremental cost per CIN2+ case
detected was US$48 for VIA/VILI and US$814 for careHPV. Despite higher costs, careHPV
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was more sensitive for CIN2+ cases detected compared to VIA/VILI (97% and 56%, respec-
tively). The cost of colposcopy was US$6.6 per person while directed biopsy was US$33.0
and 4Q biopsy was US$48.0.
Conclusion
Depending on the willingness to pay for the detection of a case of cervical cancer, decision
makers in Burkina Faso can consider a variety of cervical cancer screening strategies for
WLHIV. While careHPV is more costly, it has the potential to be cost-effective depending on
the willingness to pay threshold. Future research should explore the lifetime costs and bene-
fits of cervical cancer screening to enable comparisons with interventions for other
diseases.
Introduction
In Burkina Faso, like in many countries in sub-Saharan Africa (SSA), invasive cervical cancer
is the leading cause of female cancer mortality [1]. The current cervical cancer screening
modality in Burkina Faso is visual inspection using acetic acid with the possibility to add
Lugol’s iodine (VIA/VILI), but information on uptake is sparse and perceived to be low [2],
and effectiveness to prevent cancer remains unmeasured in the Burkinabe context. Compared
to HIV-negative women, women living with HIV (WLHIV) are at higher risk of persistent
high-risk human papillomavirus (HPV) infections, which are aetiologically linked to the devel-
opment of precursor cervical intraepithelial neoplasia (CIN) lesions, ultimately leading to
increased risk of invasive cervical cancer (ICC) [3,4]. HIV care programmes in SSA have sel-
dom been designed to integrate cervical cancer screening, despite ICC being considered an
AIDS-defining illness [5]. Thanks to increasing access to antiretroviral therapy (ART),
WLHIV have increased life expectancy; and recent studies suggest that early ART, with suffi-
cient duration of use accompanied with sustained HIV viral suppression, may reduce inci-
dence of ICC by as much as 60% [6].
While cytology based on stained cervical scrapes or smears (Papanicolaou method) has
been the traditional method for screening in high income countries, HPV DNA testing has
been increasingly advocated because of its high sensitivity to detect high-grade cervical intrae-
pithelial neoplasia (CIN2+) [7]. These methods complemented by high-level clinical services
offering colposcopy, biopsy for confirmatory histological diagnosis and management of cervi-
cal lesions once detected have been credited with considerable declines in cervical cancer mor-
tality in high-income countries [8] where rates are seven to 10 times lower than low-income
countries [1]. Cervical cancer screening programmes using cytology or HPV DNA tests are
more difficult to implement and sustain in low and middle income countries (LMICs) due to
logistical, financial and human resource constraints [9], although efforts are being made in
some LMICs to introduce HPV based testing [10]. At the time of this study, Burkina Faso, had
only three hospitals (one public) in Ouagadougou, the capital city, that offered the Papanico-
laou test [11]. Cervical cancer screening was opportunistic and population-based programmes
were not available.
In order to expand access to cervical cancer screening, less resource-intensive techniques
are being employed, such as VIA/VILI that can be performed by trained nurses and midwives
who can immediately treat lesions with cryotherapy (screen and treat approach). Another
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option is triage using lab-based HPV DNA tests such as careHPV (QIAGEN Inc, Gaithesburg,
MD) [12–16], which involves a second screening test because of its low specificity. Visual
inspection has shown to have reasonable sensitivity and specificity for CIN2+/CIN3+ in the
general population [17], but can be highly variable depending on setting and operator training
and experience [18]. It is unclear if diagnostic accuracy of visual inspection is dependent on
HIV status, as few studies evaluating diagnostic accuracy by HIV status report conflicting find-
ings [19,20]. The pooled sensitivity of VIA for CIN2+ in HIV-negative women in SSA has
been shown to vary from 76% to 87% [17]. The careHPV DNA test has had satisfactorily high
and equivalent sensitivity in various settings among HIV-seronegative women [21] and in
WLHIV [22] but lower specificity to distinguish CIN2+ among WLHIV due to higher preva-
lence of HR-HPV in WLHIV [22,23].
To date there has been limited costing evidence on cervical screening in SSA [9,24,25], and
the cost-effectiveness of the careHPV test against histological outcomes has only been assessed
in a handful of countries [14,16,26]. A recent systematic review of the cost-effectiveness of cer-
vical cancer screening strategies in LMICs (not limited to WLHIV) indicated that visual
inspection and HPV testing are more cost-effective than cytology and that the cost-effective-
ness of HPV testing was dependent on the test costs and performance of visual inspection [9].
The frequent and intensive follow-up of patients at HIV clinics may provide a valuable oppor-
tunity to organise cervical cancer screening. Targeting WLHIV is a commonly recommended
policy option in SSA [27]; however, this has been limited in implementation. Few studies have
investigated the costs and cost-effectiveness of integrating cervical cancer screening into HIV
services, and none of these studies have been conducted in Burkina Faso [24,26]. For example,
a cost study in Kenya indicated that integrating cervical screening through VIA, VIA/VILI,
careHPV, Papanicolaou, or Hybrid Capture II (HC-II) into HIV services would be less costly
than a non-integrated programme due to economies of scope (i.e. efficiencies due to broaden-
ing services offered) [24].
Our study reports the costs of screening (VIA, VIA/VILI, cytology, HPV) and confirmatory
tests (colposcopy, histology) from a health provider perspective in Burkina Faso. The incre-
mental cost per additional CIN2+ case detected using screening or triage strategies for
WLHIV attending HIV clinics in Burkina Faso is also evaluated.
Methods
A cross-sectional study of cervical cancer screening strategies was conducted among WLHIV
aged between 25 and 50 years who were enrolled from the Hopital de Jour HIV clinic of the
Centre Hospitalier Universitaire Yalgado Ouédraogo (CHU-YO) between November 2011
and April 2012. CHU-YO is the largest HIV clinic in the country, located in Ouagadougou,
Burkina Faso. The HPV in Africa Research Partnership (HARP) methodology has been
described elsewhere [28]. The HARP study was given approval by the research ethics commit-
tees of the Wits University in South Africa (no. 110707), the Ministry of Health in Burkina
Faso (no. 2012-12-089), and the London School of Hygiene & Tropical Medicine (no. 7400).
Written informed consent was obtained at the screening visit when eligibility for the study was
assessed and at enrolment. In brief, all eligible and consenting women were screened using
VIA, VILI, careHPV, and cytology in one visit. Eligibility criteria were women aged 25–50
years who were HIV-1 seropositive, resident in the city, who had not had any treatment for
cervical cancer or hysterectomy, who were not pregnant or less than 8 weeks postpartum. For
cytology, ‘test-positivity’ was considered if atypical squamous cells of undetermined signifi-
cance, or greater (ASCUS+). Thresholds for test-positivity using low-grade squamous intrae-
pithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL) were also
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considered. All participants, regardless of screening test results, were invited for colposcopy
and women showing any anomaly on any of the screening tests or during colposcopic exami-
nation were subjected to systematic four-quadrant (4Q) cervical biopsy including directed
biopsy of any suspect area to obtain the diagnosis of CIN by histology. Women found to have
no anomaly for all tests did not undergo biopsy and were considered CIN negative. In this
paper, VIA, VIA/VILI, careHPV, and cytology are referred to as screening tests while colpos-
copy and 4Q biopsy and followed by histology are termed confirmatory tests. Whilst the costs
of all aforementioned tests are reported here, only the screening tests are included in the cost-
effectiveness analysis.
Diagnostic accuracy of screening strategies
CIN2+ prevalence was calculated based on diagnosis of CIN2+ from the study endpoint classi-
fication consensus by a panel of five pathologists in the HARP study [29]. Test performance
was evaluated among the women recruited into the HARP study using local diagnostic out-
comes as the reference test in calculation of the diagnostic accuracy of the index tests (VIA,
VILI, cytology, HPV). Since the careHPV tests did not arrive in time for the study start, the
diagnostic accuracy was taken from the HC-II HPV DNA test (also manufactured by QIAGEN
Inc, Gaithesburg, MD). Excellent agreement (94.6%) between these tests was observed in the
HARP population [30].
Screening strategies were defined as any standalone screening test or two screening tests
conducted in series (triage options). For triage options, the second test is only conducted
amongst those who test positive for the first test. The joint sensitivity of both tests within a
strategy is reported for all participants screened, which increases the overall specificity of the
triage option as compared with individual test accuracies or multiple tests in parallel. The
number of cases detected was calculated by multiplying the joint sensitivity of the screening
test(s) by the prevalence of CIN2+ in the population.
Cost data
The cost data were collected during a one-month period in June 2012 and a one-week period
in April 2013 in the HIV outpatient clinic and pathology laboratory in CHU-YO and from the
CERBA laboratory in Ouagadougou. The cost analysis adopted a health care provider perspec-
tive (i.e. the facility providing the screening and care) [31]. An ingredients-based costing meth-
odology was used, where quantities of resources were multiplied by their respective unit prices
to obtain total costs per woman screened. Information was collected by direct observation of
capital (equipment) and recurrent (personnel and consumables) resources used for each
screening and diagnostic procedure. Resource use was collected only for activities directly
related to the procedures, and costs related to the study were excluded. The time was taken
from the mean of 10 women for each diagnostic and confirmatory test using a stopwatch. For
the timings of the clinical procedures needed for each test, client preparation time and time
spent on conducting the actual procedure were recorded separately to allow for disaggregation
of the different screening procedures. The costs of VIA and VILI were collected separately and
then grouped as a single procedure for combined VIA/VILI exam. Laboratory procedures
were also observed for 10 procedures except for careHPV (when the test became available),
which was only observed three times due to the need to do batch testing of 88 samples. The
collection and analysis of careHPV test results in HARP has been previously described [23].
For the personnel costs, gross salaries were obtained from local salary data from the Minis-
try of Health and included basic salary, housing allowance, night shift allowance, risk allow-
ance and responsibility analysis for personnel costs. The average cost per hour of working time
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was obtained by dividing the annual salary of the staff member by the number of working
hours (40 hours per week with 30 days annual leave and 14 official holidays) [32]. The average
time spent by each staff member for each screening test per woman was multiplied by the aver-
age cost per minute of working time per staff member. Capital costs were annualised based on
using local life expectancies of 2 to 10 years for equipment at the standard discount rate of 3%
[33] and divided by the annual throughputs. Overhead costs related to all cervical cancer
screening and confirmatory tests were applied at 25% of the total capital and recurrent costs
[12]; this assumption was varied in the sensitivity analysis.
Costs do not include Value Added Tax as medical programmes and associated goods are
exempt from it in Burkina Faso [34]. Whenever prices were obtained in another currency, the
annual exchange rate for 2012 was used to convert into West African Francs (XOF) to get the
in country price [35]. Costs are reported in United States Dollars (US$) using the average
exchange rate for 2012 (US$ 1 = XOF 503.1) [35], and then inflated to 2019 US$ [36]. Credible
ranges were not calculated for the costs.
Due to using the joint sensitivity of triage options, the total costs will vary depending on the
number of tests given for the second screening test while the cases detected will be limited by
the test with the lower sensitivity. For strategies requiring two laboratory test components, it
was assumed that samples for both tests would be taken during the first clinical visit and that
the sample for the second test would be analysed only if the first test was positive. For triage
options with VIA/VILI, only options that gave the laboratory test second were examined as the
cost of increased laboratory work for the non-VIA/VILI test and cost of an additional clinic
visit cost guaranteed that giving a laboratory test first would be more expensive and therefore
dominated in the cost-effectiveness analysis.
Routine practice for obtaining biopsies is to collect directly from a lesion seen during
colposcopy (i.e. directed biopsy). Accordingly, the cost of a directed biopsy was calculated to
compare with the systematic 4Q biopsy used under the study protocol, which may be advo-
cated because of its potential increased sensitivity. The directed biopsy costs were calculated
using assumptions based on interviews with study and site staff. Patient preparation, colpos-
copy and post-procedure time remained the same as for 4Q biopsy. For clinic staff time, the
procedure time for the biopsy was divided by four to get the time for one biopsy. For labora-
tory staff time and consumables, the time was divided by two because the four samples were
processed on two slides. Clinical consumables remained the same apart from only needing one
container for the biopsy sample instead of two. Equipment costs remained the same.
Cost-effectiveness analysis
Screening strategies were given to a hypothetical cohort of 1000 WLHIV over a time horizon
from screening to diagnosis of CIN2+, which would range from the day of testing for VIA/
VILI to months after taking the test for careHPV. Costs and outcomes were not discounted.
Under the active follow up of the HARP study, the time from screening to CIN2+ diagnosis
ranged from one to nine months, but this may take longer in reality. For triage options, all
women received the first screening test but only the proportion who tested positive for the
screening test received the second test so that:
Cwoman screened ¼ Cs1 � Ns1 þ Cs2 � Ns2
where Cs1 is the cost of the first screening test, Ns1 is the cohort size, Cs2 is the cost of the sec-
ond screening test, and Ns2 is the percentage of women requiring the confirmatory test multi-
plied by the cohort size (i.e. those testing positive for the screening test). Since the sample for
the second screening test was taken at the time of first test, no loss to follow up was assumed.
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While the costs of confirmatory tests were not included in the cost-effectiveness analysis, the
percentage of women that would need a colposcopy and the associated additional cost per
cohort was reported alongside the number without CIN2+ receiving a colposcopy because of a
positive screening test or triage strategy. In this way, the costs of false positives were incorpo-
rated into the second test of triage strategies in the cost-effectiveness analysis, and the costs of
false negatives are not incorporated.
When comparing the options, screening strategies were ranked by cost and those that were
dominated because they cost more and found fewer cases were removed as options. For those
remaining screening strategies, incremental cost-effectiveness ratios (ICERs) were calculated




Where Cost is the total cost of a screening strategy and Cases is the total number of CIN2
+ cases detected for the corresponding strategy. For the first ICER calculated, the least costly
option as the base case, and screening strategies that had cost-effectiveness ratios higher than
the next, more effective, alternative were also removed due to extended dominance. While this
analysis provides information on the cost per true case CIN2+ identified, it is limited in that it
does not attempt to capture the long-term health impact of detecting a case, such as cases
averted or life years saved.
Sensitivity analyses
Parameters key to the incremental cost per additional CIN2+ case detected were varied in a
one-way sensitivity analysis to investigate their impact on the results. The first analysis on the
costs involved varying the flat rate on the overheads to 10% to get a low cost scenario and to
75% to approximate a high cost scenario [12]. In addition, the sensitivity of the screening strat-
egies was increased and decreased by 20%.
As careHPV has not been widely introduced in SSA, detailed costings are reported here and
a univariate sensitivity analysis was done on parameters to assess the impact of alternative
assumptions on careHPV visit costs. The components of the careHPV test that were supplied
by Qiagen included the careHPV brush, collection medium, test kit and machine; these were
examined separately in the sensitivity analysis. Parameters examined in the univariate sensitiv-
ity analysis included: careHPV test component costs, consumable costs (excluding careHPV
test components), equipment costs (excluding careHPV test components), staff costs, the
number of women screened per clinic per year, the number of specimens per careHPV kit
used, and the addition of laboratory training for careHPV. For VIA/VILI and cytology, a uni-
variate analysis examined the impact of increasing and decreasing the costs by 20%. Finally,
best and worst case scenarios were created using the lowest and highest values for all parame-
ters for each test.
A threshold analysis was conducted on the cost of the careHPV screening strategies to see
at what cost a screening strategy involving careHPV would become as cost-effective as the next
best option. The total cost of items that were in addition to the careHPV test components is
subtracted from this cost to find the price that the test components from Qiagen would need
to be to get the strategy to be the most cost-effective option.
Results
In total, 615 WLHIV were included in the HARP cohort in Burkina Faso, of whom 554 had
histology results. The number of women with available screening strategy results ranged from
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526 to 553. The median age was 36 years (inter-quartile range [IQR], 31–41). The prevalence
of CIN2+ was 5.8% (95% confidence interval [CI]: 4.0–8.1).
Table 1 shows the costs and clinical time required per screening or confirmatory test.
Screening tests were done in clinic by a nurse/midwife while confirmatory tests involved a
gynaecologist assisted by a midwife. The average clinical time for each screening procedure
was around 8 minutes with 95% CIs ranging from six to 10 minutes. The confirmatory tests
took longer with a range from 13 minutes for colposcopy to 22 minutes for colposcopy with
4Q biopsy. Fig 1 shows the total costs per screening or confirmatory test. While cost of the
screening tests ranged from US$3.2 for VIA to US$24.8 for cytology, confirmatory test costs
ranged from US$6.6 for colposcopy without biopsy to US$48.0 with 4Q biopsy. Colposcopy
with directed biopsy was US$33.0. The cost of 4Q biopsy was higher than directed biopsy
mainly due to increases in pathology costs. The cost of each test broken down by components
are shown in S1 Table.
Table 2 shows the cost per woman screened and incremental cost per CIN2+ case detected.
The sensitivity of standalone test strategies ranged from 30% for HSIL cytology to 97% for car-
eHPV. For the triage strategies, the joint sensitivity ranged from 23% for VIA/VILI followed by
HSIL cytology to 70% for the combinations of LSIL cytology and careHPV. The range of costs per
woman screened was US$3–34 while careHPV was US$23. The sensitivity of VIA/VILI was 56%.
Adding careHPV to VIA/VILI increased the costs per woman screened by US$5 compared to
VIA/VILI alone but did not change the sensitivity (56%). With an ICER of US$48 (range: US$37–
60) compared with VIA (the least costly option), VIA/VILI was one of the two screening strategies
that was not dominated along with careHPV (ICER = US$382, range: US$638–1014). It is impor-
tant to note that while careHPV was the most expensive non-dominated option; it was also the
screening strategy with the highest sensitivity (97%). Increasing the cost-effectiveness of these
strategies would depend on the willingness to pay threshold per case of CIN2+ detected. None of
the triage strategies were cost-effective as compared to single screening test strategies. This is
because the increased cost of the second screening test compounded by finding fewer cases (or
the same number of cases) due to the joint sensitivity. The one-way sensitivity analysis on the sen-
sitivity of the screening options did not change which options were cost-effective (S2 Table).
Table 1. Clinical timings and clinical and laboratory costs per person tested.
Type of procedure Mean clinical time (minutes) Total clinical costs Total laboratory costs Total costs (-/+20%)
Screening Tests
VIA 7.8 (5.9 to 12.2) $3.2 (3.1–3.5) $0.0 $3.2 (2.6–3.9)
VIA/VILI 8.6 (6.4 to 13.6) $3.6 (3.4–3.9) $0.0 $3.5 (2.9–4.3)
Cytology 8.5 (6.5 to 11.9) $6.6 (6.4–6.8) $18.3 $24.8 (19.8–29.8)
careHPV 8.4 (6.2 to 11.7) $5.5 (5.4–5.7) $21.8 $27.3 (21.8–32.8)
Confirmatory tests
Colposcopy 13.1 (10.0 to 14.9) $6.6 (6.4–6.7) $0.0 $6.6 (5.3–7.9)
Colposcopy and four-quadrant biopsy2 21.8 (16.9 to 25.7) $11.8 (11.5–12.0) $36.1 $47.9 (38.4–57.5)
Colposcopy and directed biopsy2,3 16.7 (13.1 to 18.6) $10.6 (10.3–10.7) $22.4 $33.0 (26.4–39.6)
1Times are for midwife. Midwife times were slightly higher than gynaecologist times due to preparation responsibilities.
2The directed biopsy times and costs are estimated by interview and were not directly observed. Assumes that only one biopsy was taken.
Abbreviations: careHPV, HPV DNA test; VIA = visual inspection with acetic acid; VIA/VILI, combined visual inspection with Lugol’s iodine.
All costs are in United States dollars (2019). Ranges for clinical time and clinical costs use the minimum and maximum values for clinical time. The range for the total
costs is -/+20% of the base case estimate.
https://doi.org/10.1371/journal.pone.0248832.t001
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Table 3 shows the main input parameters for screening via careHPV, and Fig 2 shows the
results of the sensitivity analysis on these. The univariate analysis showed that the careHPV
test cost had the highest impact on screening costs followed by laboratory staff training costs.
The worst-case analysis for careHPV showed the costs increasing to US$42.1 per woman, just
over twice the base case scenario.
The threshold analysis showed that careHPV would only become as cost-effective as VIA/
VILI (i.e. have an ICER of US$48) if careHPV could be implemented without incurring lab
training costs and if test components (machine, kit, sample medium and brush) were provided
free of charge. Since it is unlikely that careHPV could be implemented without any of those
costs, the threshold analysis indicates that cost per true case detected would certainly increase
when using careHPV as compared to VIA/VILI. It is important to note, however, that this
Fig 1. Unit costs of screening and confirmatory tests in 2019 United States Dollars.
https://doi.org/10.1371/journal.pone.0248832.g001
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switch would also increase the percentage of true cases found from 56% to 97%, potentially
reducing the long-term healthcare costs for these women.
Discussion
To our knowledge, this is the first study to report the cost-effectiveness for a wide range of cer-
vical cancer screening strategies among WLHIV in Burkina Faso. These included currently
recommended strategies in low-resource settings (VIA or VIA/VILI), cytology, and the HPV
DNA test in the form of a rapid test (careHPV). Using cost data collected alongside a large
evaluation study of screening approaches with systematic and rigorous histological endpoint
determination, our analysis demonstrated a wide range in both the costs (US$3–34 per woman
screened) and the sensitivity of the screening strategies (23–98%) to detect CIN2+. Testing
costs were similar to the costs of integrating cervical cancer screening into HIV clinics in
Kenya [24] and generally lower than those reported in WLHIV in South Africa [26]. The




























Base case Low cost High cost
VIA 44% 80% 13% $3.2 25 21% (210) 18% (184) $1,377
VIA/VILI 56% 78% 8% $3.6 32 $48 $42 $67 24% (239) 21% (206) $1,567
VIA/VILI
+ careHPV








40% 93% 55% $8.6 23 (dominated) (dominated) (dominated) 9% (87) 6% (64) $569
careHPV 97% 62% 48% $22.7 56 $814 $717 $1,140 42% (418) 36% (361) $2,744
HSIL
cytology
30% 97% 14% $24.8 17 (dominated) (dominated) (dominated) 5% (45) 3% (28) $296
LSIL
cytology
















70% 88% 95% $34.1 40 (dominated) (dominated) (dominated) 16% (158) 12% (118) $1,036
Abbreviations: careHPV, HPV DNA test; CIN2+, high-grade cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesions; LSIL, low-grade
squamous intraepithelial lesions; VIA, visual inspection with acetic acid; VIA/VILI, combined visual inspection with Lugol’s iodine.
For triage options, the sensitivity, specificity, and positive predictive values are joint for both tests. The low cost incremental cost-effectiveness ratio uses 10% for
overheads while the high cost uses 75% for overheadsa.
a For the cytology tests, this is the sensitivity of cytology to detect HSIL or LSIL.
https://doi.org/10.1371/journal.pone.0248832.t002
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South African study showed that even when HPV DNA lab test costs were reduced to US$1
(2013), it would not be cost-effective as compared to the Papanicolaou test due to the lower
specificity of HPV DNA testing compared to cervical cytology, which is standard care in this
setting and performs with high sensitivity and specificity ensured by established infrastructure,
expertise and external quality assessment programme in place [26].
No organised national screening programme or integration of cervical cancer screening
into HIV care was in existence in Burkina Faso at the time of the study [11], and women often
presented at late stages of cervical cancer and that were diagnosed clinically. Further barriers
to screening in Burkina Faso included educational and socioeconomic barriers [37]. In target
populations for cervical cancer screening such as WLHIV, the higher prevalence of cervical
precancer would drive down the costs, thereby increasing the cost-effectiveness. Our results
showed that the addition of VILI to VIA, the current screening modality in Burkina Faso
increased sensitivity for CIN2+ from 44% to 56%, adding evidence to that provided by
Muwonge et al. from Burkina Faso and other countries that demonstrated that VIA/VILI has a
higher sensitivity than VIA alone [38]. While this would be considered too low for an effective
screening strategy, the additional cost of VILI was only US$0.4 per woman screened, and the
sensitivity was higher for CIN3+ (85%) [39]. In Burkina Faso, the HIV prevalence is now less
than 1% [40]. In a study of sex workers in Bobo Dioulasso, Burkina Faso, 12% of WLHIV had
HSIL lesions versus 1% in those who were HIV-seronegative [41]. If this trend follows to the
rest of the population, then targeting WLHIV in HIV clinics provides an opportunity to detect
and manage CIN2+ cases in order to prevent cervical cancer in a small proportion of the popu-
lation who is at a much higher risk in a cost-effective way.
Recent WHO guidelines recommend HPV DNA triaged by visual inspection and a stand-
alone HPV DNA test followed by treatment for low and middle-income countries [27]. In any
triage combination involving careHPV and VIA/VILI, our results indicate that visual inspec-
tion followed by careHPV would have a lower cost compared to careHPV followed by visual
inspection, due to the lower unit cost of visual inspection. careHPV cost US$19 more per
Table 3. Selected input parameters for careHPV in 2019 United States Dollars.
Parameter Input Assumptions
careHPV test costs
careHPV cervical sample brush $0.56 Quote from Qiagen invoice for HARP.
careHPV collection medium $1.12
careHPV kit (96-well) $1,079
careHPV machine $22,484
Lifetime of careHPV machine 5 years Local practice for similar equipment.
Time needed for laboratory
technician to process one 96-well
kit
4 hours & 3
minutes
Average of three observations. This includes hands off time.
Number of samples processed in
96-well kit
88 The test requires at least 4 controls per kit and an additional 2
blanks interspaced in panel to control for possible
contamination (our practice, not manufacturer
recommendation) and it was assumed that not every batch
would be completely full.
Monthly salary
Midwife $525 Assumes that one third are Certified Midwife 1 and two thirds
are Certified Midwife 2&3.
Lab technician $572 Assumes that half are laboratory technicians and half are
senior laboratory technicians.
Sample carrier $219 Assumes that it takes 2 minutes to transport from clinic to on
site laboratory and handover specimen.
https://doi.org/10.1371/journal.pone.0248832.t003
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woman screened than visual inspection. As both tests could be combined in one visit, this
would result in a lower risk of loss to follow-up. In our study, the addition of VIA/VILI to car-
eHPV resulted in a large decrease in sensitivity from 97% using careHPV alone to 56%, similar
to that reported by others [22]. Frequent training and quality control for VIA/VILI may
improve its diagnostic accuracy. In our study, nurses received training at study initiation only.
Visual inspection may also have greater sensitivity to detect CIN3+ due to the larger lesions
observed. When comparing standalone tests, VIA/VILI cost less per case detected than car-
eHPV but missed nearly half (44%) of CIN2+. Increasingly the evidence indicates that the
diagnostic accuracy of VIA/VILI is highly variable, although visual inspection enhanced with
automated evaluation approaches report greater accuracy for CIN2+ [42,43]. While our analy-
sis indicates that VIA/VILI is cost-effective compared to VIA alone and careHPV, it is hard to
ignore the capability of DNA testing to detect 97% of cases.
Our study has a number of limitations. Firstly, due to issues with sourcing the tests in
the timeframe needed for this study, the diagnostic accuracy results of careHPV were
Fig 2. One-way sensitivity analysis of the cost per woman screened with careHPV, cytology and visual inspection with acetic acid and Lugol’s iodine (VIA/VILI) in
2019 United States Dollars (US$).
https://doi.org/10.1371/journal.pone.0248832.g002
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derived from the performance of Digene HC-II in the HARP population; however, the
diagnostic accuracy for careHPV and Digene HC-II tests was similar in a subset of HARP
participants [30]. Accordingly, the costs for careHPV were used with the diagnostic accu-
racy from the Digene HC-II test, and differences in diagnostic accuracy could impact the
ICER. Secondly, the costs of confirmatory tests, treatment and losses-to-follow-up were
not included. The overall costs of confirmatory tests would be dependent on the specificity
of the screening strategy but would result in a decrease in over-treatment. Loss to follow
up circumvents the health gains that screening provides, and a lifetime model would be
needed to capture the costs and health outcomes associated with it. While treatment
increases the costs, the advantages of expedited diagnosis and treatment are recognised,
including among WLHIV in South Africa [44], but are not captured in our analysis. In
this study setting where the detection and treatment of CIN2+ were paid for by the study,
none of the women refused colposcopy and only one did not receive the proposed treat-
ment. In Burkina Faso, where the costs for procedures range from US$10 for cryotherapy
to US$200 for hysterectomy, few women will be able or willing to pay these fees. Accord-
ingly, public sector funding for the improvement of cervical cancer care needs to be care-
fully considered before implementing a screening program. A third of the women in this
study (31%) were not on ART at enrolment, so earlier ART may impact the effectiveness
of screening, particularly as the diagnostic accuracy of screening increases with higher
CD4 counts [22,45].
Finally, while cost per additional CIN2+ case detected is a useful measure for comparing
various screening strategies with each other, it does not answer whether screening in HIV clin-
ics is a cost-effective option as compared to other interventions to prevent cervical cancer or as
compared to interventions for other diseases. A model of the lifetime costs and benefits of cer-
vical cancer screening programs using the cost per disability-adjusted life-year averted would
be more appropriate as it would capture the long-term costs and benefits whilst enabling com-
parison with competing health interventions for other diseases [46]. A lifetime model would
also be able to account for differences in the frequency of screening tests and possibly how
these need to differ in WLHIV as compared to the general population. Cost per CIN2+ case
detected, however, is more informative than the cost per woman screened, which can be used
as a unit cost in future cost-effectiveness analyses.
Conclusions
This study reports the costs of different screening strategies and diagnostic confirmatory tests
for cervical cancer in WLHIV in Burkina Faso and the cost-effectiveness of screening and tri-
age strategies. Our analysis showed that VIA/VILI alone and careHPV alone are potentially
cost-effective options for cervical cancer screening for WLHIV in Burkina Faso, depending on
the willingness-to-pay for each additional case detected. Whilst careHPV cost US$814 more
per true case CIN2+ detected, its sensitivity was 97% as compared to 56% for VIA/VILI.
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